Symptoms and QOL with Ceritinib in ALK plus NSCLC Patients with/without Brain Metastases

被引：0
|
作者：
Crino, Lucio [1 ]
Ahn, Myung-Ju [2 ]
De Marinis, Filippo [3 ]
Groen, H. J. M. [4 ,5 ]
Wakelee, Heather A. [6 ]
Hida, Toyoaki [7 ]
Mok, Tony [8 ]
Shaw, Alice [9 ]
Felip, Enriqueta [10 ]
Nishio, Makoto [11 ]
Scagliotti, Giorgio V. V. [12 ]
Branle, Fabrice [13 ]
Emeremni, Chetachi [14 ]
Sutradhar, Santosh [15 ]
Quadrigli, Massimiliano [13 ]
Zhang, Jie [15 ]
Spigel, David [16 ]
机构：
[1] Perugia Hosp, Perugia, Italy
[2] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea
[3] European Inst Oncol, Thorac Oncol Div, Milan, Italy
[4] Univ Groningen, Groningen, Netherlands
[5] Univ Med Ctr Groningen, NL-9713 AV Groningen, Netherlands
[6] Stanford Univ, Dept Med, Div Oncol, Stanford, CA 94305 USA
[7] Aichi Canc Ctr, Dept Thorac Oncol, Nagoya, Aichi 464, Japan
[8] Chinese Univ Hong Kong, Shatin, Hong Kong, Peoples R China
[9] Massachusetts Gen Hosp, Boston, MA 02114 USA
[10] Vall DHebron Univ Hosp, Barcelona, Spain
[11] Japanese Fdn Canc Res, Tokyo, Japan
[12] Univ Turin, Turin, Italy
[13] Novartis Pharma AG, Basel, Switzerland
[14] Novartis Pharma AG, E Hanover, NJ USA
[15] Novartis Pharmaceut, E Hanover, NJ USA
[16] Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2015年 / 10卷 / 09期
关键词：
ALK Inhibitor; brain metastases; Patient-reported outcomes; Ceritinib;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MINI31.13
引用
收藏
页码：S379 / S379
页数：1
相关论文
共 50 条
  • [41] PD-1 inhibitors plus chemotherapy in EGFR/ALK-positive NSCLC patients with brain metastases and disease progression after EGFR/ALK-TKIs therapy
    Zhu, Yixiang
    Zhang, Ye
    Hu, Xingsheng
    Wang, Mingzhao
    Wang, Hongyu
    Liu, Yutao
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (12) : 3557 - 3566
  • [42] Effectiveness of ALK inhibitors in treatment of CNS metastases in NSCLC patients
    Gil, Michal
    Knetki-Wroblewska, Magdalena
    Nizinski, Przemyslaw
    Strzemski, Maciej
    Krawczyk, Pawel
    ANNALS OF MEDICINE, 2023, 55 (01) : 1018 - 1028
  • [43] PD-1 inhibitors plus chemotherapy in EGFR/ALK-positive NSCLC patients with brain metastases and disease progression after EGFR/ALK-TKIs therapy
    Yixiang Zhu
    Ye Zhang
    Xingsheng Hu
    Mingzhao Wang
    Hongyu Wang
    Yutao Liu
    Journal of Cancer Research and Clinical Oncology, 2022, 148 : 3557 - 3566
  • [44] Outcomes in patients with NSCLC with brain metastases
    Valiyaveettil, D.
    Malik, M.
    Joseph, D.
    Ahmed, S. F.
    Sindhusha, K.
    ANNALS OF ONCOLOGY, 2017, 28
  • [45] Immunotherapy in NSCLC Patients with Brain Metastases
    Buriolla, Silvia
    Pelizzari, Giacomo
    Corvaja, Carla
    Alberti, Martina
    Targato, Giada
    Bortolot, Martina
    Torresan, Sara
    Cortiula, Francesco
    Fasola, Gianpiero
    Follador, Alessandro
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (13)
  • [46] Zykadia® (Ceritinib) in the First Line leads to advanced, ALK-positive NSCLC to a PFS of 16.6 or 26.3 Months, if no Brain Metastases were present at the Time of Diagnosis
    Dinkhoff, Karen
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 (03) : 160 - 160
  • [47] Genetic landscape of ALK plus non-small cell lung cancer (NSCLC) patients (pts) and response to ceritinib in ASCEND-1.
    Tan, Daniel Shao-Weng
    Kim, Dong-Wan
    Thomas, Michael
    Pantano, Serafino
    Wang, Ying
    Szpakowski, Sebastian Lukasz
    Yovine, Alejandro Javier
    Mehra, Ranee
    Chow, Laura Q.
    Sharma, Sunil
    Solomon, Benjamin J.
    Felip, Enriqueta
    Camidge, D. Ross
    Vansteenkiste, Johan F.
    Bitter, Hans
    Petruzzelli, Lilli M.
    Dugan, Margaret Han
    Shaw, Alice T.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [48] Brain metastases in patients with ALK plus non-small cell lung cancer: clinical symptoms, treatment patterns and economic burden
    Guerin, Annie
    Sasane, Medha
    Zhang, Jie
    Culver, Kenneth W.
    Dea, Katherine
    Nitulescu, Roy
    Wu, Eric Qiong
    JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (04) : 312 - 322
  • [49] Continuation of ceritinib beyond disease progression is associated with prolonged post-progression survival (PPS) in ALK plus NSCLC
    Tan, D.
    Liu, G.
    Kim, D-W.
    Thomas, M.
    Felip, E.
    Signorovitch, J.
    Zhang, J.
    Szczudlo, T.
    Shaw, A. T.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S134 - S135
  • [50] Cost analysis of the management of brain metastases in patients with advanced ALK+ NSCLC: alectinib versus crizotinib
    Isla, Dolores
    Massuti, Bartomeu
    Lazaro, Martin
    Ruiz de Alda, Lucia
    Gordo, Rocio
    Ortega-Joaquin, Nuria
    Oyaguez, Itziar
    LUNG CANCER MANAGEMENT, 2020, 9 (01)
12345